Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 1 1

Status

Unknown 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 2NETWORK 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Thoracic 24CNS 4Lymphoid 2Tumor-Agnostic 1Plasma cell 1Other hematologic neoplasm 1Other 1Myeloid 1Genitourinary 1Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Meningeal Carcinomatosis 2Brain Neoplasms 2Neuroblastoma 1Glioma 1Glioblastoma 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × lorlatinib × CNS × Clear all
NCT06282874 2026-04-09

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Guangdong Association of Clinical Trials

Phase 4 Active not recruiting
41 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06333899 2026-03-12

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Nationwide Children's Hospital

Phase EARLY_PHASE1 Recruiting
15 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Glioblastoma, Glioma

NCT03107988 2025-09-15

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
65 enrolled 38 charts
CNS

Neuroblastoma

NCT06410040 2024-05-10

A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis

Sichuan Cancer Hospital and Research Institute

Unknown
28 enrolled
CNS

Brain Neoplasms, Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡